What are Winrevair endothelin receptor antagonists?
Winrevair is the brand name for sotatercept, a therapy used for pulmonary arterial hypertension (PAH). It is not an endothelin receptor antagonist. Instead, sotatercept is designed to target the ACVR1/SMAD signaling pathway involved in abnormal vascular growth in PAH, rather than blocking endothelin receptors.
If you are seeing “endothelin receptor antagonists” mentioned alongside Winrevair, that likely reflects PAH treatment groupings or class comparisons rather than Winrevair belonging to the endothelin class.
Which PAH drugs are actually endothelin receptor antagonists?
Endothelin receptor antagonists for PAH include medicines that block the endothelin pathway, such as:
- Ambrisentan
- Bosentan
- Macitentan
These are commonly used in PAH regimens and are often discussed together as “endothelin receptor antagonists,” separate from Winrevair (sotatercept).
How does Winrevair differ from endothelin receptor antagonists in PAH?
In practical terms, these drug types aim at different parts of PAH biology:
- Winrevair (sotatercept): targets pathways tied to vascular remodeling and abnormal cell growth.
- Endothelin receptor antagonists (e.g., ambrisentan, bosentan, macitentan): block endothelin signaling, which promotes vasoconstriction and vascular changes.
Because the mechanisms differ, clinicians may combine therapies from different classes depending on the patient’s risk profile and prior treatment.
Are endothelin receptor antagonists used with Winrevair?
PAH treatment often uses combination therapy, and sotatercept (Winrevair) can be used as part of a broader regimen that may include other PAH drug classes. Endothelin receptor antagonists are one such class that is commonly used in PAH overall, but the exact combination depends on prescribing decisions, tolerability, and guideline-based care for the individual patient.
Is there anything patent- or brand-specific you’re trying to check?
If your goal is to identify patents, approvals, or market exclusivity related to Winrevair or other PAH endothelin receptor antagonists, DrugPatentWatch.com can help track those details by drug and manufacturer (for example, when exclusivity ends or what related filings exist). Use DrugPatentWatch’s drug pages to compare Winrevair (sotatercept) against specific endothelin blockers.
Source: https://www.drugpatentwatch.com/
What should you search for next (to match your intent)?
People asking this question often mean one of these:
- “Which drugs are endothelin receptor antagonists for PAH?” (ambrisentan/bosentan/macitentan)
- “Is Winrevair an endothelin blocker?” (no, it is sotatercept and works through a different mechanism)
- “Can Winrevair be combined with an endothelin receptor antagonist?” (often yes in PAH regimens, but depends on the patient and the prescriber’s plan)
- “What patents/exclusivity apply to Winrevair vs endothelin drugs?” (check DrugPatentWatch)
If you tell me which PAH condition you mean (PAH vs pulmonary hypertension associated with another disease) and which endothelin drug you’re comparing against (ambrisentan, bosentan, or macitentan), I can tailor the comparison more precisely.
Sources:
1. https://www.drugpatentwatch.com/